(2026). Camrelizumab Plus Apatinib in Advanced Unresectable Alveolar Soft Part Sarcoma and Undifferentiated Pleomorphic Sarcoma Patients: A Single-Center, Exploratory Case Series. Therapeutics and Clinical Risk Management.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Camrelizumab Plus Apatinib in Advanced Unresectable Alveolar Soft Part Sarcoma and Undifferentiated Pleomorphic Sarcoma Patients: A Single-Center, Exploratory Case Series."
Therapeutics and Clinical Risk Management 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Camrelizumab Plus Apatinib in Advanced Unresectable Alveolar Soft Part Sarcoma and Undifferentiated Pleomorphic Sarcoma Patients: A Single-Center, Exploratory Case Series."
Therapeutics and Clinical Risk Management, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.